|
FL2 siRNA as a Novel Therapeutic Option to Induce Spinal Cord Regeneration Following Injury |
1R21NS126890-01A1 |
|
NINDS |
2022 |
|
Intranasal Delivery of Telomerase Reverse Transcriptase mRNA for Therapy ofTraumatic Brain Injury |
1R21NS127265-01A1 |
|
NINDS |
2022 |
|
Rapidly healing flow diverters using magnetic cell targeting for intracranial aneurysm treatment |
1R21NS128199-01 |
|
NINDS |
2022 |
|
Blood-Biomarkers and Risk Factors of Acute Brain Injury associated with Neurodisability in Ugandan Children [BRAIN-Child] |
1R21NS129234-01 |
|
NINDS |
2022 |
|
The Atp7b-/- mouse model of neurological copper toxicity and Wilson Disease |
1R21NS130270-01 |
|
NINDS |
2022 |
|
Noninvasive Vagus Nerve Stimulation for Treatment of Brain Injury (nVNS-TBI) in Rats |
1R21NS130423-01 |
|
NINDS |
2022 |
|
KPTN Loss and Megalencephaly: mTOR Activation as Therapeutic Target |
1R37NS125632-01 |
|
NINDS |
2022 |
|
Improved Diagnosis of Shunt Malfunction with Automatic Quantification of Ventricular Space |
1R41NS125874-01 |
|
NINDS |
2022 |
|
GPR39 as a Therapeutic Target in Subarachnoid Hemorrhage (SAH) |
1R41NS127634-01 |
|
NINDS |
2022 |
|
Pharmacokinetics and efficacy of intrathecal VersaMab-101 delivery foracute spinal cord injury |
1R43NS127712-01 |
|
NINDS |
2022 |